title: Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Leclerc
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Lesesve
authors.forename: Baptiste
authors.initials: B
authors.lastname: Gaillard
authors.forename: Xavier
authors.initials: X
authors.lastname: Troussard
authors.forename: Ayman
authors.initials: A
authors.lastname: Tourbah
authors.forename: Marc
authors.initials: M
authors.lastname: Debouverie
authors.forename: Sylvie
authors.initials: S
authors.lastname: Daliphard
authors.forename: Alain
authors.initials: A
authors.lastname: Delmer
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab